{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:34:01Z","timestamp":1792704841484,"version":"4.5.0"},"reference-count":55,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"crossref","award":["P01 CA250972"],"award-info":[{"award-number":["P01 CA250972"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,4,14]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Rationale<\/jats:title>\n                  <jats:p>Androgen deprivation therapy (ADT) is pivotal in treating recurrent prostate cancer and is often combined with external beam radiation therapy (EBRT) for localized disease. However, for metastatic castration-resistant prostate cancer, EBRT is typically only used in the palliative setting, because of the inability to radiate all sites of disease. Systemic radiation treatments that preferentially irradiate cancer cells, known as radiopharmaceutical therapy or targeted radionuclide therapy (TRT), have demonstrable benefits for treating metastatic prostate cancer. Here, we explored the use of a novel TRT, <jats:sup>90<\/jats:sup>Y-NM600, specifically in combination with ADT, in murine prostate tumor models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>6-week-old male FVB mice were implanted subcutaneously with Myc-CaP tumor cells and given a single intravenous injection of <jats:sup>90<\/jats:sup>Y-NM600, in combination with ADT (degarelix). The combination and sequence of administration were evaluated for effect on tumor growth and infiltrating immune populations were analyzed by flow cytometry. Sera were assessed to determine treatment effects on cytokine profiles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>ADT delivered prior to TRT (ADT\u2192TRT) resulted in significantly greater antitumor response and overall survival than if delivered after TRT (TRT\u2192ADT). Studies conducted in immunodeficient NRG mice failed to show a difference in treatment sequence, suggesting an immunological mechanism. Myeloid-derived suppressor cells (MDSCs) significantly accumulated in tumors following TRT\u2192ADT treatment and retained immune suppressive function. However, CD4+ and\u2009CD8+ T cells with an activated and memory phenotype were more prevalent in the ADT\u2192TRT group. Depletion of Gr1+MDSCs led to greater antitumor response following either treatment sequence. Chemotaxis assays suggested that tumor cells secreted chemokines that recruited MDSCs, notably CXCL1 and CXCL2. The use of a selective CXCR2 antagonist, reparixin, further improved antitumor responses and overall survival when used in tumor-bearing mice treated with TRT\u2192ADT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The combination of ADT and TRT improved antitumor responses in murine models of prostate cancer, however, this was dependent on the order of administration. This was found to be associated with one treatment sequence leading to an increase in infiltrating MDSCs. Combining treatment with a CXCR2 antagonist improved the antitumor effect of this combination, suggesting a possible approach for treating advanced human prostate cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-008760","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T02:46:31Z","timestamp":1714013191000},"page":"e008760","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using <sup>90<\/sup>Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03689699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03473925","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03805594","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03658447","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anusha","family":"Muralidhar","sequence":"first","affiliation":[{"name":"Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5558-3547","authenticated-orcid":false,"given":"Zachary S","family":"Morris","sequence":"additional","affiliation":[{"name":"Human Oncology, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel","family":"Comas Rojas","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malick","family":"Bio Idrissou","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamey P","family":"Weichert","sequence":"additional","affiliation":[{"name":"Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-6723","authenticated-orcid":false,"given":"Douglas G","family":"McNeel","sequence":"additional","affiliation":[{"name":"Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"2025100301075007000_12.4.e008760.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4788"},{"key":"2025100301075007000_12.4.e008760.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.01.034"},{"key":"2025100301075007000_12.4.e008760.3","unstructured":"Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer - PubMed. 2023. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/9323260\/"},{"key":"2025100301075007000_12.4.e008760.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70474-7"},{"key":"2025100301075007000_12.4.e008760.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"2025100301075007000_12.4.e008760.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0231"},{"key":"2025100301075007000_12.4.e008760.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573"},{"key":"2025100301075007000_12.4.e008760.8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-Dcfpyl in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"2025100301075007000_12.4.e008760.9","doi-asserted-by":"publisher","DOI":"10.1021\/bc200279b"},{"key":"2025100301075007000_12.4.e008760.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025100301075007000_12.4.e008760.11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.semradonc.2021.09.003","article-title":"Mechanisms, challenges, and opportunities in combined radiation and hormonal therapies","volume":"32","author":"Coulter","year":"2022","journal-title":"Semin Radiat Oncol"},{"key":"2025100301075007000_12.4.e008760.12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0172"},{"key":"2025100301075007000_12.4.e008760.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214670","article-title":"Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway","volume":"14","author":"Sekhar","year":"2019","journal-title":"PLOS ONE"},{"key":"2025100301075007000_12.4.e008760.14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3747\/co.v17i5.632","article-title":"Combining radiation therapy and androgen deprivation for localized prostate cancer\u2014a critical review","volume":"17","author":"Dal Pra","year":"2010","journal-title":"Curr Oncol"},{"key":"2025100301075007000_12.4.e008760.15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2021.10.027","article-title":"The evolving role of immune cells in prostate cancer","volume":"525","author":"Wang","year":"2022","journal-title":"Cancer Lett"},{"key":"2025100301075007000_12.4.e008760.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-02973-1","article-title":"Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration","volume":"11","author":"Long","year":"2020","journal-title":"Cell Death Dis"},{"key":"2025100301075007000_12.4.e008760.17","doi-asserted-by":"crossref","first-page":"1055826","DOI":"10.3389\/fendo.2022.1055826","article-title":"Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front Endocrinol"},{"key":"2025100301075007000_12.4.e008760.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2499"},{"key":"2025100301075007000_12.4.e008760.19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6098"},{"key":"2025100301075007000_12.4.e008760.20","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0145"},{"key":"2025100301075007000_12.4.e008760.21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s43018-021-00227-3","article-title":"Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression","volume":"2","author":"Lopez-Bujanda","year":"2021","journal-title":"Nat Cancer"},{"key":"2025100301075007000_12.4.e008760.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870"},{"key":"2025100301075007000_12.4.e008760.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.06.032"},{"key":"2025100301075007000_12.4.e008760.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9020013","article-title":"Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy","volume":"9","author":"Kalina","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2025100301075007000_12.4.e008760.25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007646","article-title":"Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy","volume":"6","author":"Weichert","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025100301075007000_12.4.e008760.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111652","article-title":"A phase 1 study of 131I-Clr1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety","volume":"9","author":"Grudzinski","year":"2014","journal-title":"PLoS One"},{"key":"2025100301075007000_12.4.e008760.27","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131014","article-title":"Fractionated dosing of CLR 131 in patients with Relapsed or refractory multiple myeloma (RRMM)","volume":"134","author":"Ailawadhi","year":"2019","journal-title":"Blood"},{"key":"2025100301075007000_12.4.e008760.28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/07357907.2015.1081691","article-title":"A phase 1, multi-center, open-label, dose-escalation study of 131I-Clr1404 in subjects with Relapsed or refractory advanced solid malignancies","volume":"33","author":"Lubner","year":"2015","journal-title":"Cancer Invest"},{"key":"2025100301075007000_12.4.e008760.29","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2967\/jnumed.118.224808","article-title":"Preclinical characterization of 86\/90Y-Nm600 in a variety of murine and human cancer tumor models","volume":"60","author":"Grudzinski","year":"2019","journal-title":"J Nucl Med"},{"key":"2025100301075007000_12.4.e008760.30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s42003-019-0327-4","article-title":"90Y-Nm600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell non-Hodgkin\u2019s lymphoma","volume":"2","author":"Hernandez","year":"2019","journal-title":"Commun Biol"},{"key":"2025100301075007000_12.4.e008760.31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders Immunologically cold tumors responsive to immune Checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025100301075007000_12.4.e008760.32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of 90 Y-Nm600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100301075007000_12.4.e008760.33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.apradiso.2018.09.016","article-title":"Simplified and automatable radiochemical separation strategy for the production of radiopharmaceutical quality 86Y using single column extraction chromatography","volume":"142","author":"Aluicio-Sarduy","year":"2018","journal-title":"Appl Radiat Isot"},{"key":"2025100301075007000_12.4.e008760.34","first-page":"155","article-title":"Development and validation of RAPID: a patient-specific Monte Carlo three-dimensional internal dosimetry platform","volume":"33","author":"Besemer","year":"2018","journal-title":"Cancer Biother Radiopharm"},{"key":"2025100301075007000_12.4.e008760.35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/HP.0000000000000789","article-title":"Murine-specific internal dosimetry for preclinical investigations of imaging and therapeutic agents","volume":"114","author":"Bednarz","year":"2018","journal-title":"Health Phys"},{"key":"2025100301075007000_12.4.e008760.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0241-8"},{"key":"2025100301075007000_12.4.e008760.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70223-0"},{"key":"2025100301075007000_12.4.e008760.38","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30528-x"},{"key":"2025100301075007000_12.4.e008760.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01904"},{"key":"2025100301075007000_12.4.e008760.40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): a pooled analysis of 12 randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100301075007000_12.4.e008760.41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010020","article-title":"The response of prostate cancer to androgen deprivation and irradiation due to immune modulation","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025100301075007000_12.4.e008760.42","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"2025100301075007000_12.4.e008760.43","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24068"},{"key":"2025100301075007000_12.4.e008760.44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41585-020-0328-6","article-title":"Androgen deprivation as a tumour-Immunomodulating treatment","volume":"17","author":"Gamat-Huber","year":"2020","journal-title":"Nat Rev Urol"},{"key":"2025100301075007000_12.4.e008760.45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41391-022-00615-5","article-title":"Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis","volume":"26","author":"Bronte","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025100301075007000_12.4.e008760.46","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010020","article-title":"Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives","volume":"11","author":"Koinis","year":"2021","journal-title":"Cells"},{"key":"2025100301075007000_12.4.e008760.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0855"},{"key":"2025100301075007000_12.4.e008760.48","first-page":"3257","article-title":"Challenges and prospects of CSF1R targeting for advanced malignancies","volume":"13","author":"Moeller","year":"2023","journal-title":"Am J Cancer Res"},{"key":"2025100301075007000_12.4.e008760.49","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4049\/jimmunol.155.4.2158","article-title":"Chemokine binding and activities mediated by the mouse IL-8 receptor","volume":"155","author":"Lee","year":"1995","journal-title":"J Immunol"},{"key":"2025100301075007000_12.4.e008760.50","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1111\/cas.13809","article-title":"Chemokine (C-X-C motif) ligand 1 and CXCL2 produced by tumor promote the generation of Monocytic myeloid-derived Suppressor cells","volume":"109","author":"Shi","year":"2018","journal-title":"Cancer Sci"},{"key":"2025100301075007000_12.4.e008760.51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246293","article-title":"Suppressing MDSC recruitment to the tumor Microenvironment by antagonizing Cxcr2 to enhance the efficacy of Immunotherapy","volume":"13","author":"Bullock","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100301075007000_12.4.e008760.52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-021-06367-5","article-title":"A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)","volume":"190","author":"Goldstein","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2025100301075007000_12.4.e008760.53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2463"},{"key":"2025100301075007000_12.4.e008760.54","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12488"},{"key":"2025100301075007000_12.4.e008760.55","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and Sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clin Experimental Allergy"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:07:59Z","timestamp":1759478879000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,24]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/jitc-2023-008760"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008760","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}